ECM
AVDL

Endurant Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Endurant Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-87,676
Closed -$696K – 59
2020
Q1 		$696K Buy
+87,676
New +$673K 0.32% 40
2018
Q2 		– Sell
-55,700
Closed -$406K – 67
2018
Q1 		$406K Buy
+55,700
New +$490K 0.15% 67

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Endurant Capital Management's AVDL Position: Q2 2020 in Review

Endurant Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2020, closing a stake of 87,676 shares — an estimated $696K sold.

Endurant Capital Management first reported a position in AVDL in Q1 2018 and held it in 2 quarters. The position peaked at $696K in Q1 2020. 74 funds tracked by Wall St. Rank hold AVDL as of Q2 2020.

  • Endurant Capital Management reported no remaining Avadel Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Endurant Capital Management sold 87,676 Avadel Pharmaceuticals shares in Q2 2020, an estimated $696K.
  • Endurant Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Endurant Capital Management's Avadel Pharmaceuticals position peaked at $696K in Q1 2020.
  • 74 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2020.

Based on Endurant Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.